- Guide to PHARMACOLOGY
Compound class: Endogenous peptide in human, mouse or rat
Comment: CXCL13 is a C-X-C motif homeostatic chemokine that is selectively chemotactic for B cells belonging to both the B-1 and B-2 subsets. It exerts its biological effects via binding to the chemokine receptor CXCR5. CXCL13 expression can be regulated by the lymphotoxin β receptor (LTBR) pathway, and it contributes to ectopic tertiary lymphoid tissue development at sites of chronic inflammation in several autoimmune diseases, for example in the lacrimal and salivary glands of Sjögren's patients . The CXCL13/LTBR axis is considered as a potential therapeutic target in conditions like Sjögren's syndrome. This is evidenced by the development of pharmaceutical agents that block LTBR activity being advanced to clinical trials (e.g. baminercept (BG9924) which is a soluble LTBR-IgG Fc fusion protein ).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|CXCL13 is involved in shaping B-cell dynamics to enhance antigen encounter and BCR-triggered B-cell activation .|
||Serum CXCL13 is elevated in patients with SS, compared to healthy controls. Expression of CXCL13 in ectopic lymphoid-like follicles in salivary glands of SS patients has been suggested as a potential disease marker. CXCL13 levels are reduced by blockade of lymphotoxinβ receptor in the NOD mouse model of SS.||1,4-5|